The global connected drug delivery devices market size was estimated to be USD 6.04 billion in 2023 and is expected to reach at USD 67.00 billion by 2034 with a CAGR of 24.46% during the forecast period 2024-2034. Increasing cost of medical management, a heightened demand to enhance patient treatment outcomes, shift in preferences towards home-based care, surge in prevalence of chronic diseases, growing emphasis on preventive care, widespread adoption of connected devices in laboratories & hospitals for the upkeep of Electronic Health Records (EHR), increasing research & development activities, growing need to improve patient medication adherence, and rising launch of advanced connected drug delivery devices are some of the key factors boosting the market growth.
Rising launch of advanced connected drug delivery devices is predicted to boost the market growth during the forecast period. Connected drug delivery devices, referred to as smart wireless electronic systems, play a crucial role in supporting patient monitoring and counselling within residential settings. Equipped with sensors, adherence trackers, dose reminders, and monitoring systems, these devices provide real-time feedback and personalized educational resources for patient care. They offer a convenient and cost-effective alternative to clinic-based treatments. Consequently, connected drug delivery devices are commonly employed in the remote monitoring of individuals with various conditions, including asthma, diabetes, hepatitis C, hypertension, tuberculosis, multiple sclerosis, clinically isolated syndrome, Chronic Obstructive Pulmonary Disease (COPD), and those who have undergone liver and kidney transplants. in June 2023, Stevanato Group has introduced Vertiva, a patented on-body drug delivery system that allows the seamless transition between basal and bolus injections for a range of subcutaneous therapies. Developed in partnership with Thermo Fisher Scientific, this device will be available as a comprehensive integrated fill-and-finish solution. Vertiva includes a single-use pod containing a pre-filled 3mL ISO cartridge and a reusable controller, emphasizing sustainability and cost-effectiveness. The device is adaptable to various delivery profiles and is capable of administering both small-molecule drugs and biologics.
By product, standalone components & software was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the rising demand for connected sensors to convert conventional drug delivery devices into connected versions, ensuring that this transformation does not disrupt their fundamental functionality, increase in technological innovation, and the introduction of connectivity devices. For instance, in February 2022, Aptar Pharma has introduced HeroTracker Sense, an add-on for metered-dose inhalers (MDI) that transforms a regular inhaler into a smart connected drug delivery device. Additionally, integrated devices is predicted to grow at the fastest CAGR during the forecast period owing to the increasing availability of integrated connected drug delivery devices. These integrated devices serve dual purposes, facilitating both injection and inhalational delivery systems. This capability empowers patients to manage their medication therapy even in remote locations.
By route of administration, parenteral was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the growing preference for smart & connected parenteral devices due to the various benefits they provide compared to traditional devices, increasing incidence of chronic diseases such as diabetes, cancer, neurological disorders, and a heightened emphasis on the creation of innovative devices. For instance, in April 2023, Researchers at Northwestern University have created a self-powered drug delivery device designed for implantation in the human body. The team is currently assessing its biocompatibility and safety features before seeking FDA approval for human clinical trials. Additionally, inhalational is predicted to grow at the fastest CAGR during the forecast period owing to the increasing occurrence of respiratory conditions including asthma & Chronic Obstructive Pulmonary Disorders (COPD), rise in research & development endeavors, a growing focus on employing digital devices to enhance treatment outcomes, and increase in the introduction of new products by major companies.
By technology, bluetooth was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the increased adoption of technology to establish connections between drug delivery devices and smartphones, enhanced compatibility of Bluetooth technology with various drug delivery devices, user-friendly interfaces, and a rising trend of collaborations among market players. For instance, in January 2023, Biogen has recently entered into a licensing and collaboration arrangement with Alcyone Therapeutics to advance the ThecaFlex DRx system. This subcutaneous drug delivery system is tailored for the treatment of neurological disorders like SMA and ALS. ThecaFlex is an advanced medical device designed specifically to deliver treatments precisely into the cerebrospinal fluid. It consists of an implantable intrathecal catheter, a catheter fixation device, and a subcutaneous port system. The collaboration will primarily focus on clinically developing the system for antisense oligonucleotide (ASO) therapies. Additionally, NFC is predicted to grow at the fastest CAGR during the forecast period owing to the various advantages, including prolonged battery life and enhanced data transmission capabilities.
By application, diabetes Management was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the growing incidence of diabetes and expanding research & development activities in the field of insulin delivery devices. Additionally, others is predicted to grow at the fastest CAGR during the forecast period owing to the increase in technological advancements and a rise in mergers & acquisitions among market players. This encompasses autoimmune diseases such as multiple sclerosis, migraine, and osteoporosis. For instance, in April 2023, Lohmann Therapie-Systeme (LTS) has acquired Sorrel's wearable injection device business, incorporating a platform for delivering large-molecule drugs into its portfolio. Sorrel specializes in pre-loaded wearable devices designed for the subcutaneous administration of large-molecule drugs, offering options like devices with internal drug reservoirs as well as pre-filled cartridges and vials. LTS's CEO has confirmed that Sorrel's drug delivery platform is set for commercial launch in 2023, utilizing LTS's global presence to ensure scalability. This acquisition propels LTS into the realm of large-molecule drug delivery, aligning with its commitment to provide impactful solutions for patients relying on costly therapies.
By end-user, homecare settings was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the growing demand to enhance patient experience, increasing prevalence of COPD & asthma, rising healthcare infrastructure, surge in need for home-based treatment for the expanding geriatric population, and growing introduction of new devices. For instance, in May 2022, Jabil Healthcare, a division of Jabil Inc., has introduced the Qfinity autoinjector platform in the United States. This is a reusable device designed for the self-administration of subcutaneous (SC) drugs. Additionally, the product is available in a connected option. Additionally, hospitals is predicted to grow at the fastest CAGR during the forecast period owing to the rise in the incidence of cardiovascular diseases (CVDs), diabetes, chronic obstructive pulmonary disease (COPD), & other health conditions, increase in innovations related to connected drug delivery devices, a growing emphasis on achieving enhanced procedural outcomes, and the rapid development of healthcare infrastructure.
North America region is anticipated for the highest revenue share during the forecast period owing to the swift integration of advanced technologies, the prominence of key market players, an increasing embrace of remote monitoring to enhance medication adherence, and growing introduction of advanced technologies. For instance, in January 2023, Medtronic plc has declared that its AccuRhythm AI algorithm technology secured the title of "Best New Monitoring Solution" in the 7th annual MedTech Breakthrough Awards program. AccuRhythm AI, an artificial intelligence algorithm, enhances the precision of heart rhythm event data collected from the Medtronic LINQ II™ insertable cardiac monitor (ICM), enabling physicians to provide improved care for individuals experiencing abnormal heart rhythms. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing incidence of chronic diseases, the presence of a substantial patient population, and the expanding collaborations among market players. For instance, in September 2022, Adherium Limited has revealed a collaborative partnership with CareCentra Inc. aimed at enhancing the care for Chronic Obstructive Pulmonary Disease (COPD) and Asthma through the development of an innovative disease management suite. CareCentra intends to integrate Adherium's Hailie platform, which includes the latest U.S. FDA cleared digital sensors capturing physiological data and technique parameters, into their Artificial Intelligence (AI) Driven Behaviour Shaping platform, known as MyMoBeMapTM.
Rising launch of advanced connected drug delivery devices is predicted to boost the market growth during the forecast period. Connected drug delivery devices, referred to as smart wireless electronic systems, play a crucial role in supporting patient monitoring and counselling within residential settings. Equipped with sensors, adherence trackers, dose reminders, and monitoring systems, these devices provide real-time feedback and personalized educational resources for patient care. They offer a convenient and cost-effective alternative to clinic-based treatments. Consequently, connected drug delivery devices are commonly employed in the remote monitoring of individuals with various conditions, including asthma, diabetes, hepatitis C, hypertension, tuberculosis, multiple sclerosis, clinically isolated syndrome, Chronic Obstructive Pulmonary Disease (COPD), and those who have undergone liver and kidney transplants. in June 2023, Stevanato Group has introduced Vertiva, a patented on-body drug delivery system that allows the seamless transition between basal and bolus injections for a range of subcutaneous therapies. Developed in partnership with Thermo Fisher Scientific, this device will be available as a comprehensive integrated fill-and-finish solution. Vertiva includes a single-use pod containing a pre-filled 3mL ISO cartridge and a reusable controller, emphasizing sustainability and cost-effectiveness. The device is adaptable to various delivery profiles and is capable of administering both small-molecule drugs and biologics.
By product, standalone components & software was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the rising demand for connected sensors to convert conventional drug delivery devices into connected versions, ensuring that this transformation does not disrupt their fundamental functionality, increase in technological innovation, and the introduction of connectivity devices. For instance, in February 2022, Aptar Pharma has introduced HeroTracker Sense, an add-on for metered-dose inhalers (MDI) that transforms a regular inhaler into a smart connected drug delivery device. Additionally, integrated devices is predicted to grow at the fastest CAGR during the forecast period owing to the increasing availability of integrated connected drug delivery devices. These integrated devices serve dual purposes, facilitating both injection and inhalational delivery systems. This capability empowers patients to manage their medication therapy even in remote locations.
By route of administration, parenteral was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the growing preference for smart & connected parenteral devices due to the various benefits they provide compared to traditional devices, increasing incidence of chronic diseases such as diabetes, cancer, neurological disorders, and a heightened emphasis on the creation of innovative devices. For instance, in April 2023, Researchers at Northwestern University have created a self-powered drug delivery device designed for implantation in the human body. The team is currently assessing its biocompatibility and safety features before seeking FDA approval for human clinical trials. Additionally, inhalational is predicted to grow at the fastest CAGR during the forecast period owing to the increasing occurrence of respiratory conditions including asthma & Chronic Obstructive Pulmonary Disorders (COPD), rise in research & development endeavors, a growing focus on employing digital devices to enhance treatment outcomes, and increase in the introduction of new products by major companies.
By technology, bluetooth was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the increased adoption of technology to establish connections between drug delivery devices and smartphones, enhanced compatibility of Bluetooth technology with various drug delivery devices, user-friendly interfaces, and a rising trend of collaborations among market players. For instance, in January 2023, Biogen has recently entered into a licensing and collaboration arrangement with Alcyone Therapeutics to advance the ThecaFlex DRx system. This subcutaneous drug delivery system is tailored for the treatment of neurological disorders like SMA and ALS. ThecaFlex is an advanced medical device designed specifically to deliver treatments precisely into the cerebrospinal fluid. It consists of an implantable intrathecal catheter, a catheter fixation device, and a subcutaneous port system. The collaboration will primarily focus on clinically developing the system for antisense oligonucleotide (ASO) therapies. Additionally, NFC is predicted to grow at the fastest CAGR during the forecast period owing to the various advantages, including prolonged battery life and enhanced data transmission capabilities.
By application, diabetes Management was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the growing incidence of diabetes and expanding research & development activities in the field of insulin delivery devices. Additionally, others is predicted to grow at the fastest CAGR during the forecast period owing to the increase in technological advancements and a rise in mergers & acquisitions among market players. This encompasses autoimmune diseases such as multiple sclerosis, migraine, and osteoporosis. For instance, in April 2023, Lohmann Therapie-Systeme (LTS) has acquired Sorrel's wearable injection device business, incorporating a platform for delivering large-molecule drugs into its portfolio. Sorrel specializes in pre-loaded wearable devices designed for the subcutaneous administration of large-molecule drugs, offering options like devices with internal drug reservoirs as well as pre-filled cartridges and vials. LTS's CEO has confirmed that Sorrel's drug delivery platform is set for commercial launch in 2023, utilizing LTS's global presence to ensure scalability. This acquisition propels LTS into the realm of large-molecule drug delivery, aligning with its commitment to provide impactful solutions for patients relying on costly therapies.
By end-user, homecare settings was the highest revenue-grossing segment in the global connected drug delivery devices market in 2023 owing to the growing demand to enhance patient experience, increasing prevalence of COPD & asthma, rising healthcare infrastructure, surge in need for home-based treatment for the expanding geriatric population, and growing introduction of new devices. For instance, in May 2022, Jabil Healthcare, a division of Jabil Inc., has introduced the Qfinity autoinjector platform in the United States. This is a reusable device designed for the self-administration of subcutaneous (SC) drugs. Additionally, the product is available in a connected option. Additionally, hospitals is predicted to grow at the fastest CAGR during the forecast period owing to the rise in the incidence of cardiovascular diseases (CVDs), diabetes, chronic obstructive pulmonary disease (COPD), & other health conditions, increase in innovations related to connected drug delivery devices, a growing emphasis on achieving enhanced procedural outcomes, and the rapid development of healthcare infrastructure.
North America region is anticipated for the highest revenue share during the forecast period owing to the swift integration of advanced technologies, the prominence of key market players, an increasing embrace of remote monitoring to enhance medication adherence, and growing introduction of advanced technologies. For instance, in January 2023, Medtronic plc has declared that its AccuRhythm AI algorithm technology secured the title of "Best New Monitoring Solution" in the 7th annual MedTech Breakthrough Awards program. AccuRhythm AI, an artificial intelligence algorithm, enhances the precision of heart rhythm event data collected from the Medtronic LINQ II™ insertable cardiac monitor (ICM), enabling physicians to provide improved care for individuals experiencing abnormal heart rhythms. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing incidence of chronic diseases, the presence of a substantial patient population, and the expanding collaborations among market players. For instance, in September 2022, Adherium Limited has revealed a collaborative partnership with CareCentra Inc. aimed at enhancing the care for Chronic Obstructive Pulmonary Disease (COPD) and Asthma through the development of an innovative disease management suite. CareCentra intends to integrate Adherium's Hailie platform, which includes the latest U.S. FDA cleared digital sensors capturing physiological data and technique parameters, into their Artificial Intelligence (AI) Driven Behaviour Shaping platform, known as MyMoBeMapTM.
Segmentation: Connected Drug Delivery Devices Market Report 2023 - 2034
Connected Drug Delivery Devices Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Integrated Devices
- Integrated Injectable Devices
- Integrated Inhalation Devices
- Standalone Components & Software
- Connected Injectable Sensors
- Connected Inhalation Sensors
Connected Drug Delivery Devices Market Analysis & Forecast by Route Of Administration 2023 - 2034 (Revenue USD Bn)
- Inhalational
- Parenteral
Connected Drug Delivery Devices Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- NFC
- Bluetooth
- Others
Connected Drug Delivery Devices Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- COPD
- Asthma
- Diabetes Management
- Others
Connected Drug Delivery Devices Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Homecare Settings
- Others
Connected Drug Delivery Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Connected Drug Delivery Devices Market: Product Estimates & Trend Analysis
8. Connected Drug Delivery Devices Market: Route Of Administration Estimates & Trend Analysis
9. Connected Drug Delivery Devices Market: Technology Estimates & Trend Analysis
10. Connected Drug Delivery Devices Market: Application Estimates & Trend Analysis
11. Connected Drug Delivery Devices Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Connected Drug Delivery Devices Market
14. Europe Global Connected Drug Delivery Devices Market
15. Asia Pacific Global Connected Drug Delivery Devices Market
16. Latin America Global Connected Drug Delivery Devices Market
17. MEA Global Connected Drug Delivery Devices Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- DENTSPLY Sirona
- Ivoclar Vivadent
- Danaher Corporation
- Zimmer Biomet
- 3M
- BioHorizons IPH
- Institut Straumann
- Biotronik
- Heraeus Kulzer
- aap Implantate AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 6.04 Billion |
| Forecasted Market Value ( USD | $ 67 Billion |
| Compound Annual Growth Rate | 24.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
